Osteologie 2020; 29(04): 317-319
DOI: 10.1055/a-1207-6028
Osteoporose-Update

Leitlinie erklärt

Friederike Thomasius

Das nächste Leitlinien-Update steht an, die Arbeit am Risikorechner, der webbasiert und evtl. auch als App eingeführt werden soll, ist Grund intensivster Arbeit der Leitliniengruppe, an erster Stelle aber von Prof. Dr. Claus Glueer und Prof. Dr. Klaus Engelke, dies seit mehr als 2 Jahren.



Publication History

Article published online:
23 November 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • Literatur

  • 1 Shepstone L, Lenaghan E, Cooper C. , et al. Screening in the community to reduce fractures in older women (SCOOP): A randomised controlled trial. Lancet 2017; 391: 741-747
  • 2 Rubin KH, Rothmann MJ, Holmberg T. , et al. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: The randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int 2018; 29: 567-578
  • 3 Merlijn T, Swart KM, van Schoor NM. , et al. The effect of a screening and treatment program for the prevention of fractures in older women: A randomized pragmatic trial. J Bone Miner Res 2019; 34: 1993-2000
  • 4 Ha T M, ThS T, Le T. , et al. Two-thirds of all fractures are not attributable to osteoporosis and advancing age: Implications for fracture prevention. J Clin Endocrinol Metab 2019; 104 (08) 3514-3520
  • 5 Trajanoska K, Schoufour JD, EAL DJ. , et al. Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: The Rotterdam Study. Bone 2018; 114: 116-124
  • 6 Reid IR, Home AM, Mihov B. , et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med 2018; 379: 2407-2416
  • 7 Gnant M, Pfeiler G, Dubsky PC. , et al. Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2018; 386: 433-443
  • 8 National Institute for Health and Care Excellence. Bisphosphonates for treating osteoporosis. https://www.nice.org.uk/guidance/ta 464 (NICE, 2019)